Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.
Type:
Grant
Filed:
November 27, 2006
Date of Patent:
December 1, 2009
Assignee:
Schering Corporation
Inventors:
Daniel M. Gorman, J. Fernando Bazan, Robert A. Kastelein, Gerard Zurawski
Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
Type:
Grant
Filed:
October 5, 2006
Date of Patent:
November 24, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Bruce L. Zamost, Hong Y. Liu, Karen S. De Jongh
Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
Type:
Grant
Filed:
October 2, 2006
Date of Patent:
November 17, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Scott R. Presnell, Steven K. Burkhead, Sarah L. Pownder
Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
Type:
Grant
Filed:
October 2, 2006
Date of Patent:
November 3, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Scott R. Presnell, Steven K. Burkhead, Sarah L. Pownder
Abstract: This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure.
Abstract: Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective amount of a zvegf3 protein in combination with a pharmaceutically acceptable delivery vehicle. Also disclosed are methods for promoting proliferation or differentiation of osteoblasts, osteoclasts, chondrocytes, or bone marrow stem cells comprising culturing the cells in an effective amount of a zvegf3 protein.
Abstract: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R?; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
Type:
Grant
Filed:
November 28, 2006
Date of Patent:
September 22, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Pallavur V. Sivakumar, Stephen R. Jaspers
Abstract: Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.
Type:
Grant
Filed:
June 18, 2004
Date of Patent:
August 25, 2009
Assignee:
The United States of America as represented by the Secretary of the Dapartment of Health and Human Services
Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
Type:
Grant
Filed:
February 11, 2004
Date of Patent:
August 25, 2009
Assignee:
Schering Corporation
Inventors:
Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
Type:
Grant
Filed:
May 4, 2006
Date of Patent:
August 4, 2009
Assignee:
Wyeth
Inventors:
Jean-Christophe Renauld, Laura Dumoutier
Abstract: Antibodies directed to the antigen IL-1? and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
Type:
Grant
Filed:
January 19, 2006
Date of Patent:
July 28, 2009
Assignee:
Amgen Fremont Inc.
Inventors:
Larry Green, Raffaella Faggioni, Orit Foord, Scott L. Klakamp, Giorgio Senaldi, Amy K. Schneider
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
July 12, 2001
Date of Patent:
July 7, 2009
Assignee:
Genentech, Inc.
Inventors:
Avi Ashkenazi, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Giang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Jennie P. Mather, James Pan, Nicholas F. Paoni, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
Abstract: The invention relates to methods and compositions for treating neural damage caused by injury or disease, by enhancing neural outgrowth and/or repair responses in the nervous system. Preferably, the methods and compositions utilize agents which interfere with the ability of the major histocompatibility complex (MHC) Class I molecule (MHC I) to inhibit neurite outgrowth. Such agents include antibodies directed to MHC I, MHC I fragments and/or analogs, and agents which interfere with MHC I interaction with its neuronal receptor and the receptor's signaling pathway.
Type:
Grant
Filed:
June 5, 2002
Date of Patent:
June 30, 2009
Inventors:
Daniel L. Kaufman, Lorraine Hanssen, Dan Zekzer
Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
April 8, 2003
Date of Patent:
June 9, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J Godowski, J Christopher Grimaldi, Austin L Gurney, William I Wood
Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
Type:
Grant
Filed:
October 21, 2005
Date of Patent:
May 26, 2009
Assignee:
ZymoGenetics, Inc.
Inventors:
Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
Abstract: This invention relates to a series of PTH and PTHrP analogues that selectively bind to PTH2 receptors and as such may be useful in treating abnormal CNS functions; abnormal pancreatic functions; divergence from normal mineral metabolism and homeostasis; male infertility; regulation of abnormal blood pressure; and hypothalmic disease.
Type:
Grant
Filed:
May 3, 1999
Date of Patent:
May 12, 2009
Assignees:
Societe de Conseils de Recherches et d'Applications Scientifiques S.A.S., Beth Israel
Inventors:
Zheng Xin Dong, Michael Chorev, Michael Rosenblatt
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 6, 2002
Date of Patent:
April 21, 2009
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
Type:
Grant
Filed:
June 6, 2000
Date of Patent:
August 18, 2009
Assignee:
Eli Lilly and Company
Inventors:
Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, Louis Vignati, William Terry Johnson